Mirae Asset Healthcare Fund Direct Growth

Fund Overview

Fund Size

₹2,236 Cr

Expense Ratio

0.50%

ISIN

INF769K01ED6

Minimum SIP

₹1,000

Exit Load

1.00%

Inception Date

02 Jun 2018

About this fund

Mirae Asset Healthcare Fund Direct Growth is a Sector - Healthcare mutual fund schemes offered by Mirae Asset India Mutual Fund. This fund has been in existence for 5 years, 11 months and 18 days, having been launched on 02-Jun-18.
As of 17-May-24, it has a Net Asset Value (NAV) of ₹34.18, Assets Under Management (AUM) of 2236.01 Crores, and an expense ratio of 0.5%.

Mirae Asset Healthcare Fund Direct Growth has given a CAGR return of 22.91% since inception.
The fund's asset allocation comprises around 99.56% in equities, 0.00% in debts, and 0.43% in cash & cash equivalents.
You can start investing in Mirae Asset Healthcare Fund Direct Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.

Performance against Category Average

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.

1 Year

+52.10%

+51.54% (Cat Avg.)

3 Years

+15.97%

+13.98% (Cat Avg.)

5 Years

+27.56%

+24.42% (Cat Avg.)

Since Inception

+22.91%

— (Cat Avg.)

Portfolio Summaryas of 30th April 2024

Equity	₹2,226.15 Cr	99.56%
Others	₹9.87 Cr	0.44%

Top Holdings

All Holdings

Equity

Debt & Others

Name	Type	Amount	Holdings
Sun Pharmaceuticals Industries Ltd	Equity	₹309.14 Cr	13.83%
Cipla Ltd	Equity	₹215.86 Cr	9.65%
Aurobindo Pharma Ltd	Equity	₹207.41 Cr	9.28%
Dr Reddy's Laboratories Ltd	Equity	₹161.53 Cr	7.22%
Apollo Hospitals Enterprise Ltd	Equity	₹134.64 Cr	6.02%
Lupin Ltd	Equity	₹95.52 Cr	4.27%
Krishna Institute of Medical Sciences Ltd	Equity	₹93.33 Cr	4.17%
Divi's Laboratories Ltd	Equity	₹91.42 Cr	4.09%
J.B. Chemicals & Pharmaceuticals Ltd	Equity	₹89.92 Cr	4.02%
Torrent Pharmaceuticals Ltd	Equity	₹86.98 Cr	3.89%
Gland Pharma Ltd	Equity	₹85.02 Cr	3.80%
Fortis Healthcare Ltd	Equity	₹80.71 Cr	3.61%
Glenmark Pharmaceuticals Ltd	Equity	₹56.83 Cr	2.54%
Max Healthcare Institute Ltd Ordinary Shares	Equity	₹55.88 Cr	2.50%
Zydus Lifesciences Ltd	Equity	₹51.82 Cr	2.32%
Syngene International Ltd	Equity	₹44.69 Cr	2.00%
Ajanta Pharma Ltd	Equity	₹44.23 Cr	1.98%
Ipca Laboratories Ltd	Equity	₹44.15 Cr	1.97%
Alkem Laboratories Ltd	Equity	₹43.68 Cr	1.95%
Mankind Pharma Ltd	Equity	₹39.89 Cr	1.78%
Max Financial Services Ltd	Equity	₹30.45 Cr	1.36%
Dr. Lal PathLabs Ltd	Equity	₹28.06 Cr	1.25%
Wockhardt Ltd	Equity	₹27.39 Cr	1.22%
Biocon Ltd	Equity	₹22.81 Cr	1.02%
Sanofi India Ltd	Equity	₹22.33 Cr	1.00%
Natco Pharma Ltd	Equity	₹22.06 Cr	0.99%
Tatva Chintan Pharma Chem Ltd	Equity	₹17.91 Cr	0.80%
Treps	Cash - Repurchase Agreement	₹14.8 Cr	0.66%
Laurus Labs Ltd	Equity	₹13.05 Cr	0.58%
Vinati Organics Ltd	Equity	₹9.46 Cr	0.42%
Net Receivables / (Payables)	Cash	₹-5.14 Cr	0.23%
Mirae Asset Liquid Dir Gr	Mutual Fund - Open End	₹0.21 Cr	0.01%

Allocation By Market Cap (Equity)

Large Cap Stocks

46.49%

Mid Cap Stocks

35.09%

Small Cap Stocks

17.98%

Other Allocation

Equity Sector

Debt & Others

Sector	Amount	Holdings
Healthcare	₹2,168.33 Cr	96.97%
Financial Services	₹30.45 Cr	1.36%
Basic Materials	₹27.37 Cr	1.22%

Risk & Performance Ratios

Standard Deviation

This fund

14.73%

Cat. avg.

14.57%

Lower the better

Sharpe Ratio

This fund

0.77

Cat. avg.

0.69

Higher the better

Sortino Ratio

This fund

Cat. avg.

1.16

Higher the better

Fund Managers

Vrijesh Kasera

Since July 2018

Additional Scheme Detailsas of 30th April 2024

	ISIN	INF769K01ED6		Expense Ratio	0.50%		Exit Load	1.00%		Fund Size	₹2,236 Cr		Age	02 Jun 2018		Lumpsum Minimum	₹5,000		Fund Status	Open Ended Investment Company		Benchmark	S&P BSE Healthcare TR INR

Investment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

Withdrawal within 1 year

Flat 15% tax on realised gains (STCG - short term capital gains)

Withdrawal after 1 year

10% tax on realised gains above Rs. 1 lakh per financial year (LTCG - long term capital gains)

Note: Mutual funds are subject to capital gains taxation with surcharge and cess, based on prevailing income tax rules and investor income. Taxation applies to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Sector - Healthcare Funds

Fund name	Expense Ratio	Exit Load	Fund size	1Y
Motilal Oswal S&P BSE Healthcare ETF Very High Risk	0.2%	-	₹13.07 Cr	54.0%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk	1.0%	1.0%	₹694.50 Cr	57.4%
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk	2.4%	1.0%	₹694.50 Cr	55.3%
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk	0.2%	-	₹36.50 Cr	52.9%
ITI Pharma and Healthcare Fund Direct Growth Very High Risk	0.4%	1.0%	₹161.86 Cr	48.4%
ITI Pharma and Healthcare Fund Regular Growth Very High Risk	2.3%	1.0%	₹161.86 Cr	45.4%
Mirae Asset Healthcare Fund Direct Growth Very High Risk	0.5%	1.0%	₹2236.01 Cr	52.1%
Mirae Asset Healthcare Fund Regular Growth Very High Risk	2.0%	1.0%	₹2236.01 Cr	49.9%
Nippon India Nifty Pharma ETF Very High Risk	0.2%	-	₹639.49 Cr	53.9%
Axis NIFTY Healthcare ETF Very High Risk	0.3%	-	₹16.41 Cr	51.7%

About the AMC

Mirae Asset India Mutual Fund

022-6780 0300

https://www.miraeassetmf.co.in/

Total AUM

₹1,63,012 Cr

Address

Unit No. 606, 6th Floor, Mumbai, 400 098

Other Funds by Mirae Asset India Mutual Fund

Fund name	Expense Ratio	Exit Load	Fund size	1Y
Mirae Asset Multi Asset Allocation Fund Direct Growth High Risk	0.4%	1.0%	₹1406.88 Cr	-
Mirae Asset Great Consumer Fund Direct Growth Very High Risk	0.4%	1.0%	₹3351.36 Cr	37.7%
Mirae Asset Cash Management Direct Growth Low to Moderate Risk	0.1%	0.0%	₹10073.98 Cr	7.3%
Mirae Asset Emerging Bluechip Direct Growth Very High Risk	0.6%	1.0%	₹34974.46 Cr	40.7%
Mirae Asset Large Cap Fund Direct Growth Very High Risk	0.5%	1.0%	₹38060.19 Cr	24.0%
Mirae Asset Savings Fund Direct Growth Moderate Risk	0.2%	0.0%	₹594.96 Cr	7.4%
Mirae Asset Money Market Fund Direct Growth Low to Moderate Risk	0.2%	0.0%	₹145.28 Cr	7.6%
Mirae Asset Focused Fund Direct Growth Very High Risk	0.6%	1.0%	₹8312.74 Cr	18.4%
Mirae Asset Dynamic Bond Fund Direct Growth Low to Moderate Risk	0.2%	0.0%	₹155.33 Cr	6.6%
Mirae Asset NYSE FANG+ ETF Fund of Fund Direct Growth Very High Risk	0.7%	0.0%	₹1570.17 Cr	80.9%
Mirae Asset Hybrid Equity Fund Direct Growth Very High Risk	0.4%	1.0%	₹8545.85 Cr	25.3%
Mirae Asset Equity Allocator Fund of Fund Direct Growth Very High Risk	0.2%	0.0%	₹705.09 Cr	34.9%
Mirae Asset Nifty 100 ESG Sector Leaders Fund of Fund Direct Growth Very High Risk	0.6%	0.0%	₹111.07 Cr	28.2%
Mirae Asset S&P 500 Top 50 ETF Fund of Fund Direct Growth Very High Risk	0.7%	0.0%	₹531.86 Cr	49.1%
Mirae Asset Nifty SDL Jun 2027 Index Fund Direct Growth Low to Moderate Risk	0.1%	0.0%	₹795.72 Cr	6.8%
Mirae Asset Ultra Short Duration Fund Direct Growth Moderate Risk	0.2%	0.0%	₹1463.94 Cr	7.6%
Mirae Asset Flexi Cap Fund Direct Growth Very High Risk	0.6%	1.0%	₹1815.41 Cr	33.8%
Mirae Asset Banking and Financial Services Fund Direct Growth Very High Risk	0.6%	1.0%	₹1702.61 Cr	24.3%
Mirae Asset Multicap Fund Direct Growth Very High Risk	0.4%	1.0%	₹2683.33 Cr	-
Mirae Asset Nifty India Manufacturing ETF Fund of Fund Direct Growth Very High Risk	0.5%	0.0%	₹78.52 Cr	60.1%
Mirae Asset Tax Saver Fund Direct Growth Very High Risk	0.6%	0.0%	₹22471.76 Cr	36.2%
Mirae Asset Nifty SDL Jun 2028 Index Fund Direct Growth Moderate Risk	0.1%	0.0%	₹83.22 Cr	6.8%
Mirae Asset Corporate Bond Fund Direct Growth Moderate Risk	0.2%	0.0%	₹49.85 Cr	6.6%
Mirae Asset Hang Seng TECH ETF Fund of Fund Direct Growth Very High Risk	0.8%	0.0%	₹72.50 Cr	7.2%
Mirae Asset Equity Savings Fund Direct Growth Moderately High risk	0.3%	1.0%	₹1019.74 Cr	17.7%
Mirae Asset Banking and PSU Debt Fund Direct Growth Moderate Risk	0.4%	0.0%	₹59.30 Cr	6.7%
Mirae Asset Global X Artificial Intelligence & Technology ETF Fund of Fund Direct Growth Very High Risk	0.9%	1.0%	₹316.95 Cr	41.2%
Mirae Asset Global Electric & Autonomous Vehicles ETFs Fund of Fund Direct Growth Very High Risk	2.0%	1.0%	₹95.84 Cr	2.8%
Mirae Asset Overnight Fund Direct Growth Low Risk	0.1%	0.0%	₹865.39 Cr	6.8%
Mirae Asset Short Term Fund Direct Growth Low to Moderate Risk	0.3%	0.0%	₹346.19 Cr	7.0%
Mirae Asset CRISIL IBX Gilt Index - April 2033 Index Fund Direct Growth Moderate Risk	0.1%	0.0%	₹225.99 Cr	6.2%
Mirae Asset Nifty AAA PSU Bond Plus SDL Apr 2026 50:50 Index Fund Direct Growth Low to Moderate Risk	0.1%	0.0%	₹103.31 Cr	6.9%
Mirae Asset Healthcare Fund Direct Growth Very High Risk	0.5%	1.0%	₹2236.01 Cr	52.1%
Mirae Asset Arbitrage Fund Direct Growth Low Risk	0.2%	0.0%	₹1870.00 Cr	8.5%
Mirae Asset Midcap Fund Direct Growth Very High Risk	0.6%	1.0%	₹15139.44 Cr	53.0%
Mirae Asset Balanced Advantage Fund Direct Growth High Risk	0.7%	1.0%	₹1570.06 Cr	22.3%

Risk Level

Your principal amount will be at Very High Risk

Still got questions?
We're here to help.

What is the current NAV of Mirae Asset Healthcare Fund Direct Growth?

The NAV of Mirae Asset Healthcare Fund Direct Growth, as of 17-May-2024, is ₹34.18.

What are the returns of Mirae Asset Healthcare Fund Direct Growth?

The fund has generated 52.10% over the last 1 year and 15.97% over the last 3 years. However, this does not guarantee that the fund will perform similarly in the future.

What is the portfolio composition of Mirae Asset Healthcare Fund Direct Growth?

The fund's allocation of assets is distributed as 99.56% in equities, 0.00% in bonds, and 0.43% in cash and cash equivalents.

Who manages the Mirae Asset Healthcare Fund Direct Growth?

The fund managers responsible for Mirae Asset Healthcare Fund Direct Growth are:-

Vrijesh Kasera

Disclaimer: Mutual Fund investments are subject to market risks, read all scheme-related documents carefully. The NAVs of the schemes may go up or down depending upon the factors and forces affecting the securities market including the fluctuations in the interest rates. The past performance of the mutual funds is not necessarily indicative of the future performance of the schemes. Investors are requested to review the prospectus carefully and obtain expert professional advice with regard to specific legal, tax and financial implications of the investment/participation in the scheme.

;

©2021-2022 Dezerv. All Rights Reserved

Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377 and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.

Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.

Mirae Asset Healthcare Fund Direct Growth

Fund Overview